

SPECTRA Search Rationale

This document explains the SPECTRA search rationale used to identify patients over the age of 18 with uncontrolled asthma. Some of the patients identified may have severe asthma.


It is the role of the Healthcare Organisation to access the list of patients generated by the SPECTRA searches and clinically review the patients identified to optimise their medication accordingly.

Patients with suspected severe asthma may require referral to a severe asthma centre for review and assessment, where appropriate patients may be considered for advanced therapies.

Rationale used to identify patients for review and assessment prior to referral

The **definition of severe asthma**, which underpins the algorithm, is **based on** the **ERS/ATS 2014 statement** which has **not been superseded**.

To **prioritise patients** for review and assessment, **each cohort** is **categorised** into **priority groups**, as shown below.



* No referral in the last 12 months or current biologic ** In the last 12 months

[‡] Priority group B is divided into those patients with < 4 OCS issues in the last 12 months & those patients with ≥ 4 OCS issues in the last 12 months

List of drugs included in Cohort 1 - High Strength ICS

Doses (*puffs and frequency*) of inhalers cannot be identified through clinical system searches. In order to identify Inhaled Corticosteroid devices that deliver high doses, strengths are used in the search criteria.

Strengths of ICS that **can** be used to **deliver both medium and high doses**¹⁰ have been **marked with an asterisk (*)**.

BECLOMETASONE

Beclometasone 200mcg dose inhaler*

Clenil Modulite pMDI 250mcg

Beclometasone 250mcg dose inhaler

Kelhale pMDI (extrafine) 100mcg*

Qvar pMDI (extrafine) 100mcg*

Qvar Autohaler (extrafine) 100mcg*

Qvar Easi-breathe (extrafine) 100mcg*

Beclometasone 100mcg breath actuated inhaler CFC free

Soprobe pMDI 250mcg

CICLESONIDE

Alvesco pMDI 160mcg*

Ciclesonide 160mcg dose inhaler*

Ciclesonide cfc-free inhaler 160mcg - 60 doses*

Ciclesonide cfc-free inhaler 160mcg - 120 doses*

FLUTICASONE

Flixotide Evohaler 250mcg

Flixotide Accuhaler 500mcg

Fluticasone propionate 500mcg dry powder inhaler

BUDESONIDE

Easyhaler (Budesonide) 400mcg

Budesonide dry powder inhaler 400mcg

Budesonide 200mcg dry powder inhalation cartridge

Budesonide 200mcg dry powder inhalation cartridge with refill

Budelin Novolizer 200mcg*

Budelin Novolizer 200mcg refill*

Pulmicort Turbohaler 400mcg*

BECLOMETASONE/FORMOTEROL

Fostair (pMDI) 200/6

Fostair (NEXThaler) 200/6

Beclometasone 200mcg /Formoterol 6mcg inhaler CFC free

Beclometasone 200mcg /Formoterol 6mcg dry powder inhaler

BUDESONIDE/FORMOTEROL

DuoResp Spiromax 320/9*

Budesonide 400mcg /Formoterol 12mcg dry powder inhaler*

Symbicort Turbohaler 400/12*

Fobumix Easyhaler 320/9*

FLUTICASONE/FORMOTEROL

Flutiform MDI 250/10

FLUTICASONE/SALMETEROL

Aerivio Spiromax 500/50

Airflusal Forspiro 500/50

AirFlusal pMDI 250/25

Aloflute pMDI 250/25

Combisal pMDI 250/25

Fusacomb Easyhaler 500/50

Sereflo pMDI 250/25

Seretide Accuhaler 500/50

Seretide Evohaler 250/25

Sirdupla pMDI 250/25

Stalpex Orbicel 500/50

Fluticasone 500mcg/ Salmeterol 50mcg inhaler CFC free

Fluticasone 250mcg/ Salmeterol 25mcg inhaler CFC free

FLUTICASONE/VILANTEROL

Relvar Ellipta 184/22

Fluticasone furoate 184mcg /Vilanterol 22mcg dry powder inhaler



List of drugs included in Cohort 2 - Other Strength ICS

This search is created by including patients on **all others strengths** of **inhaled corticosteroids** and **excluding** patients from **Cohort 1**.

Systemic corticosteroids used in the searches

Drugs in this group include **all strengths** of **tablet, solution, suspension, suppository** and **injection formulations** of **Prednisolone**:

Reliever inhalers

Drugs in this group include, **all strengths** of **short-acting beta-2 agonist (SABA)**:

- **Salbutamol**
- **Terbutaline sulfate**

References

1. Chung K F et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373
2. Bloom, C.I., Cabrera, C., Arnetorp, S. et al. Asthma-Related Health Outcomes Associated with Short-Acting Beta-2 Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. Adv Ther 37 2020, 4190–4208.
3. Crowther L, et al. "The Sentinel Project: experience-based co-design of an implementation-ready intervention to improve adult asthma care in primary care". 10th IPCRG World Conference, May 2021.